Related Experiment Video
Updated: Jul 27, 2025
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Carbon Dots in Treatment of Pediatric Brain Tumors: Past, Present, and Future Directions
Frederic A Vallejo1, Ganesh Sigdel2, Eduardo A Veliz2
1Department of Neurosurgery, Miller School of Medicine, University of Miami, 1095 NW 14th Terrace, Miami, FL 33136, USA.
Abstract:
Pediatric brain tumors remain a significant source of morbidity and mortality. Though developments have been made in treating these malignancies, the blood-brain barrier, intra- and inter-tumoral heterogeneity, and therapeutic toxicity pose challenges to improving outcomes. Varying types of nanoparticles, including metallic, organic, and micellar molecules of varying structures and compositions, have been investigated as a potential therapy to circumvent some of these inherent challenges. Carbon dots (CDs) have recently gained popularity as a novel nanoparticle with theranostic properties. This carbon-based modality is highly modifiable, allowing for conjugation to drugs, as well as tumor-specific ligands in an effort to more effectively target cancerous cells and reduce peripheral toxicity. CDs are being studied pre-clinically. The ClinicalTrials.gov site was queried using the search terms: brain tumor and nanoparticle, liposome, micelle, dendrimer, quantum dot, or carbon dot. At the time of this review, 36 studies were found, 6 of which included pediatric patients. Two of the six studies investigated nanoparticle drug formulations, whereas the other four studies were on varying liposomal nanoparticle formulations for the treatment of pediatric brain tumors. Here, we reviewed the context of CDs within the broader realm of nanoparticles, their development, promising pre-clinical potential, and proposed future translational utility.
Insights
Carbon dots (CDs) show promise for treating pediatric brain tumors by overcoming challenges like the blood-brain barrier. These novel nanoparticles offer targeted drug delivery and theranostic capabilities, with ongoing preclinical research.
Area of Science:
- Nanomedicine
- Biotechnology
- Materials Science
Background:
- Pediatric brain tumors present significant treatment challenges, including the blood-brain barrier, tumor heterogeneity, and toxicity.
- Conventional therapies are limited by these factors, necessitating novel approaches.
- Nanoparticles offer potential solutions for targeted drug delivery and overcoming treatment resistance.
Purpose of the Study:
- To review the role of carbon dots (CDs) as a novel nanoparticle platform for pediatric brain tumor therapy.
- To explore the theranostic properties and potential of CDs in preclinical settings.
- To assess the current landscape of nanoparticle research in pediatric brain tumors.
Main Methods:
- Literature review of preclinical studies on nanoparticles for brain tumors.
- Database search on ClinicalTrials.gov using keywords related to nanoparticles and brain tumors.
- Analysis of studies focusing on pediatric brain tumor treatments involving nanoparticles.
Main Results:
- Carbon dots (CDs) are emerging as versatile nanoparticles with tunable properties for drug conjugation and targeting.
- Preclinical research indicates CDs' potential to enhance drug delivery and therapeutic efficacy.
- A limited number of clinical trials (6/36) focus on pediatric brain tumors, with few investigating nanoparticle drug formulations.
Conclusions:
- Carbon dots represent a promising theranostic nanoparticle platform for addressing challenges in pediatric brain tumor treatment.
- Further preclinical development and clinical translation are warranted to realize the full potential of CDs.
- Nanoparticle-based strategies, including CDs, are crucial for advancing pediatric brain tumor therapeutics.
